Health & Life Sciences Corridor

Jordan holds an unusually complete health-economy stack: four pharmaceutical plants with U.S. FDA-recognized certification accounting for roughly 60% of pharma exports to the U.S., the region's flagship comprehensive cancer center, roughly 225,000 medical tourists generating about $1B in 2024, and a diaspora with a verified floor of at least 2,408 U.S. physicians. The highest-value realistic plays are non-clinical, and every cross-border clinical activity is explicitly out of scope. The binding constraints are equally documented: the nursing pathway depends on EB-3 visa realities, and Section 232 pharmaceutical tariffs in effect since July 31, 2026 sit outside the reciprocal framework and can invert pharma trade economics.

Narrowed to two legs per the red-team resequencing. First, HIPAA-compliant health business services exported from Jordan — medical coding and revenue-cycle management on de-identified data first, graduating to full RCM under business associate agreements — merged with the Digital & Professional Services Hub into one pilot. Second, a pharma and medtech trade and regulatory desk shepherding Jordanian ANDA and CDMO deals and packaging the documented pathway of Jordanian manufacturers to U.S. FDA recognition. A nursing-to-NCLEX pathway is presented as contingent on visa-number realities, with Gulf and domestic placement as alternate offtake.

Jordan: services export revenue, clinical-literacy employment and retained pharma manufacturing value. The U.S.: healthcare administrators gaining coding and RCM capacity in a compatible time zone, and buyers of FDA-grade manufacturing. The diaspora: physicians and health professionals contributing as mentors, faculty and compliance-adjacent advisors — never as unlicensed clinical operators.

Partner-led and deliberately narrow: JAPA as diaspora convener, KHCC and universities as research and training anchors, Jordanian pharmaceutical firms as trade-desk anchors, JNMC for licensure alignment and JFDA for the GCP/GMP interface. The Bridge's own role is limited to the trade desk and market access — the functions no existing institution performs from the U.S. side. The licensure red line is charter-level: full state licensure in the patient's location governs any clinical activity, so none is proposed.

Not yet authorized

Market context is labeled industry estimate: the U.S. medical-billing outsourcing market is projected to grow from about $7B to about $18B by 2033 (Grand View Research). The services leg's economics are modeled within the Digital Services Hub scenario (about $3.75M per year in services revenue and roughly 52 direct Jordan jobs at the base case). The trade desk's value is counted in deals sourced and inspections retained, not in headline dollars.

Scenario estimate — not a commitment, not a forecast.

Economic impact scenarios

Condition-gated on Tier-1 traction and on the merged RCM pilot's two-to-three lighthouse contracts. Discontinue or hold if any licensure or unauthorized-practice incident occurs (automatic program-wide freeze), if EB-3 retrogression exceeds 24 months with placement below 50%, if Section 232 or successor tariffs make Jordanian pharma U.S.-entry uneconomic for two consecutive quarters, or if credential-fraud exceeds 2% of verification cases.

Services revenue booked from U.S. clients; NCLEX first-time pass rate of pathway cohorts against the audited baseline; nurses placed or contracted; trade-desk deals sourced; FDA inspections passed and retained; zero unauthorized-practice incidents.

Licensure drift — charter-level exclusion of clinical services and counsel sign-off on all language. Credential fraud — primary-source verification only, zero-tolerance vendor policy. Brain-drain criticism — a circulation model with home-country leadership tracks. Tariff volatility — scenario planning before pharma features are promoted. Diaspora-count overstatement — only the verified 2,408 floor appears in official material; JAPA's ~8,000 figure is always labeled self-reported.

• concept — not funded
• Not yet authorized

All initiatives and the tier architecture · Economic impact scenarios · Governance · Roadmap